Long-chain n-3 PUFAs reduce adipose tissue and systemic inflammation in severely obese nondiabetic patients: a randomized controlled

被引：192

作者：

Itariu, Bianca K. ^{[1
,2
]}

Zeyda, Maximilian ^{[1
,2
]}

Hochbrugger, Eva E. ^{[1
]}

Neuhofer, Angelika ^{[1
,2
]}

Prager, Gerhard ^{[3
]}

Schindler, Karin ^{[1
]}

Bohdjalian, Arthur ^{[3
]}

Mascher, Daniel ^{[4
]}

Vangala, Suman ^{[1
]}

Schranz, Michael ^{[1
,2
]}

Krebs, Michael ^{[1
]}

Bischof, Martin G. ^{[5
]}

Stulnig, Thomas M. ^{[1
,2
]}

机构：

[1] Med Univ Vienna, Dept Med 3, Clin Div Endocrinol & Metab, A-1090 Vienna, Austria

[2] Med Univ Vienna, Christian Doppler Lab Cardiometab Immunotherapy, A-1090 Vienna, Austria

[3] Med Univ Vienna, Dept Gen Surg, Div Bariatr Surg, A-1090 Vienna, Austria

[4] Pharm Analyt, Baden, Austria

[5] St Elizabeth Hosp, Med Direct, Vienna, Austria

来源：

AMERICAN JOURNAL OF CLINICAL NUTRITION | 2012年 / 96卷 / 05期

基金：

欧盟第七框架计划;

关键词：

POLYUNSATURATED FATTY-ACIDS; GENE-EXPRESSION; INSULIN-RESISTANCE; DIABETIC MICE; SERUM-LIPIDS; FISH-OIL; RISK; GLUCOSE; INTERLEUKIN-6; METAANALYSIS;

D O I：

10.3945/ajcn.112.037432

中图分类号：

R15 [营养卫生、食品卫生]; TS201 [基础科学];

学科分类号：

100403 ;

摘要：

Background: Chronic adipose tissue inflammation is a hallmark of obesity, triggering the development of associated pathologies, particularly type 2 diabetes. Long-chain n-3 PUFAs reduce cardiovascular events and exert well-established antiinflammatory effects, but their effects on human adipose tissue inflammation are unknown. Objective: We investigated whether n-3 PUFAs reduce adipose tissue inflammation in severely obese nondiabetic patients. Design: We treated 55 severely obese nondiabetic patients, scheduled to undergo elective bariatric surgery, with 3.36 g long-chain n-3 PUFAs/d (EPA, DHA) or an equivalent amount of butterfat as control, for 8 wk, in a randomized open-label controlled clinical trial. The primary efficacy measure was inflammatory gene expression in visceral and subcutaneous adipose tissue samples (subcutaneous adipose tissue and visceral adipose tissue), collected during surgery after the intervention. Secondary efficacy variables were adipose tissue production of antiinflammatory n-3 PUFA-derived eicosanoids, plasma concentrations of inflammatory markers, metabolic control, and the effect of the Pro12Ala PPARG polymorphism on the treatment response. Results: Treatment with n-3 PUFAs, which was well tolerated, decreased the gene expression of most analyzed inflammatory genes in subcutaneous adipose tissue (P < 0.05) and increased production of antiinflammatory eicosanoids in visceral adipose tissue and subcutaneous adipose tissue (P < 0.05). In comparison with control subjects who received butterfat, circulating interleukin-6 and triglyceride concentrations decreased significantly in the n-3 PUFA group (P = 0.04 and P = 0.03, respectively). The Pro12Ala polymorphism affected the serum cholesterol response to n-3 PUFA treatment. Conclusions: Treatment with long-chain n-3 PUFAs favorably modulated adipose tissue and systemic inflammation in severely obese nondiabetic patients and improved lipid metabolism. These effects may be beneficial in the long-term treatment of obesity. This trial was registered at clinicaltrials.gov as NCT00760760. Am J Clin Nutr 2012;96:1137-49.

引用

页码：1137 / 1149

页数：13

共 53 条

[1] The clamp-like index -: A novel and highly sensitive insulin sensitivity index to calculate hyperinsulinemic clamp glucose infusion rates from oral glucose tolerance tests in nondiabetic subjects [J].